Roots Analysis has announced the addition of the “Fragment-based Drug Discovery Market: Library and
Service Providers, 2020-2030” report to its list
of offerings.
According to experts
in this field, fragment-based drug discovery solutions have facilitated the identification
of viable pharmacological leads against otherwise hard to target biomolecules.
In fact, many service provider companies are offering fragment libraries and
support to the medical research community in order to develop an appropriate
intervention to treat the illness caused by the SARS-CoV-2 virus.
To order this 170+ page report, which features 55+
figures and 80+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html
Key
Market Insights
Over 85 firms claim to offer fragment-based drug discovery services
and technologies
Of these, more than
40 players were observed to provide both fragment-based libraries and
technologies. It is worth mentioning that more than 55% of the service
providers use biophysical techniques, namely X-ray crystallography, surface
plasmon resonance, and nuclear magnetic resonance, for fragment screening /
optimization.
Europe has emerged as
a services hub for fragment-based drug discovery
It is worth noting
that nearly 50% of the library and service providers engaged in this field are headquartered
in Europe. This is followed players based in North America (40%) and Asia
Pacific (10%). Regions within Asia Pacific include (in decreasing order of
number of companies) China, India, and Japan.
Partnership activity within
this domain has grown at a CAGR of 74%, between 2015 and 2019
More than 65 agreements have been inked in the last five
years; majority of these were research and development agreements (55%). This
was followed by instances of merger and acquisition (19%); recent examples
include (in reverse chronological order) acquisition of Prestwick
Chemical by Domain Therapeutics (2019), Prosarix by RxCelerate (2019), and
Sierra Sensors by Bruker (2018).
According to estimates
presented in the report, by 2030, the adoption of fragment-based drug discovery
is likely to result in cost savings of over USD 6 million, per small molecule. Apart
from reducing the overall cost, this approach also enables saving in terms of time
and other resources.
By 2030, North America is anticipated to capture 50% of the
market opportunity
The market in Asia-Pacific is anticipated to grow at a
relatively faster rate (10.9%). In terms of the type of service offered, by
2030, library screening (65%) is likely to represent the largest share of the
market, followed by fragment optimization (23%) and fragment screening (12%)
services.
To request a sample
copy / brochure of this report, please visit this- https://www.rootsanalysis.com/reports/309/request-sample.html
Key Questions Answered
§
Press Release: Current Format
§
§
§
§
The USD 1.6 billion (by 2030) financial opportunity
within the fragment-based drug discovery market has been analyzed across the
following segments:
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
The report features
inputs from eminent industry stakeholders, according to whom the fragment-based
approach significantly simplifies the drug discovery process. The report
includes detailed transcripts of discussions held with the following experts:
§
§
The research covers
profiles of key players (listed below); each profile features an
overview of the company, its financial information (if available), information
related to the fragment-based drug discovery focused service portfolio, recent
developments and an informed future outlook.
§
§
§
§
§
§
§
§
§
§
§
§
§
§
For additional details,
please visit
https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html or email sales@rootsanalysis.com
You may also be
interested in the following titles:
Press Release: Current Format
1.
2.
3.
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
